These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

467 related items for PubMed ID: 23423604

  • 1. Risk of tuberculosis after antiretroviral treatment initiation: a comparison between efavirenz and nevirapine using inverse probability weighting.
    Hermans SM, Manabe YC, Kiragga AN, Hoepelman AI, Lange JM, van Leth F.
    Antivir Ther; 2013; 18(4):615-22. PubMed ID: 23423604
    [Abstract] [Full Text] [Related]

  • 2. Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin.
    Manosuthi W, Mankatitham W, Lueangniyomkul A, Chimsuntorn S, Sungkanuparph S.
    HIV Med; 2008 May; 9(5):294-9. PubMed ID: 18400076
    [Abstract] [Full Text] [Related]

  • 3. Comparing the effectiveness of efavirenz and nevirapine for first-line antiretroviral therapy in a South African multicentre cohort.
    Bock P, Fatti G, Grimwood A.
    Int Health; 2013 Jun; 5(2):132-8. PubMed ID: 24030113
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial.
    Swaminathan S, Padmapriyadarsini C, Venkatesan P, Narendran G, Ramesh Kumar S, Iliayas S, Menon PA, Selvaraju S, Pooranagangadevi NP, Bhavani PK, Ponnuraja C, Dilip M, Ramachandran R.
    Clin Infect Dis; 2011 Oct; 53(7):716-24. PubMed ID: 21890776
    [Abstract] [Full Text] [Related]

  • 5. Long-term efficacy and tolerance of efavirenz- and nevirapine-containing regimens in adult HIV type 1 Senegalese patients.
    de Beaudrap P, Etard JF, Guèye FN, Guèye M, Landman R, Girard PM, Sow PS, Ndoye I, Delaporte E, ANRS 1215/1290 Study Group.
    AIDS Res Hum Retroviruses; 2008 Jun; 24(6):753-60. PubMed ID: 18507521
    [Abstract] [Full Text] [Related]

  • 6. Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naïve patients: a cohort study.
    Keiser P, Nassar N, White C, Koen G, Moreno S.
    HIV Clin Trials; 2002 Jun; 3(4):296-303. PubMed ID: 12187503
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
    Lapphra K, Vanprapar N, Chearskul S, Phongsamart W, Chearskul P, Prasitsuebsai W, Chokephaibulkit K.
    Int J Infect Dis; 2008 Nov; 12(6):e33-8. PubMed ID: 18573672
    [Abstract] [Full Text] [Related]

  • 8. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART.
    van Leth F, Andrews S, Grinsztejn B, Wilkins E, Lazanas MK, Lange JM, Montaner J, 2NN study group.
    AIDS; 2005 Mar 25; 19(5):463-71. PubMed ID: 15764851
    [Abstract] [Full Text] [Related]

  • 9. Earlier initiation of antiretroviral therapy, increased tuberculosis case finding and reduced mortality in a setting of improved HIV care: a retrospective cohort study.
    Hermans SM, van Leth F, Manabe YC, Hoepelman AI, Lange JM, Kambugu A.
    HIV Med; 2012 Jul 25; 13(6):337-44. PubMed ID: 22296211
    [Abstract] [Full Text] [Related]

  • 10. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
    Bannister WP, Ruiz L, Cozzi-Lepri A, Mocroft A, Kirk O, Staszewski S, Loveday C, Karlsson A, Monforte Ad, Clotet B, Lundgren JD, EuroSIDA study group.
    AIDS; 2008 Jan 30; 22(3):367-76. PubMed ID: 18195563
    [Abstract] [Full Text] [Related]

  • 11. Nevirapine versus efavirenz based antiretroviral treatment in naive Indian patients: comparison of effectiveness in clinical cohort.
    Patel AK, Pujari S, Patel K, Patel J, Shah N, Patel B, Gupte N.
    J Assoc Physicians India; 2006 Dec 30; 54():915-8. PubMed ID: 17334006
    [Abstract] [Full Text] [Related]

  • 12. Predicting factors for unsuccessful switching from nevirapine to efavirenz in HIV-infected patients who developed nevirapine-associated skin rash.
    Kiertiburanakul S, Malathum K, Watcharananan S, Sathapatayavongs B, Sungkanuparph S.
    Int J STD AIDS; 2009 Mar 30; 20(3):176-9. PubMed ID: 19255265
    [Abstract] [Full Text] [Related]

  • 13. Comparative durability of nevirapine versus efavirenz in first-line regimens during the first year of initiating antiretroviral therapy among Swaziland HIV-infected adults.
    Takuva S, Evans D, Zuma K, Okello V, Louwagie G.
    Pan Afr Med J; 2013 Mar 30; 15():5. PubMed ID: 23847702
    [Abstract] [Full Text] [Related]

  • 14. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
    Abgrall S, Yeni PG, Bouchaud O, Costagliola D, Clinical Epidemiology Group from the French Hospital Database on HIV.
    AIDS; 2006 Oct 24; 20(16):2099-106. PubMed ID: 17053356
    [Abstract] [Full Text] [Related]

  • 15. Effectiveness of efavirenz-based regimens in young HIV-infected children treated for tuberculosis: a treatment option for resource-limited settings.
    van Dijk JH, Sutcliffe CG, Hamangaba F, Bositis C, Watson DC, Moss WJ.
    PLoS One; 2013 Oct 24; 8(1):e55111. PubMed ID: 23372824
    [Abstract] [Full Text] [Related]

  • 16. Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts.
    Mocroft A, Staszewski S, Weber R, Gatell J, Rockstroh J, Gasiorowski J, Panos G, Monforte Ad, Rakhmanova A, Phillips AN, Lundgren JD, EuroSIDA study group.
    Antivir Ther; 2007 Oct 24; 12(3):325-33. PubMed ID: 17591022
    [Abstract] [Full Text] [Related]

  • 17. Incidence and risk factors of nevirapine-associated skin rashes among HIV-infected patients with CD4 cell counts <250 cells/microL.
    Manosuthi W, Sungkanuparph S, Tansuphaswadikul S, Inthong Y, Prasithsirikul W, Chottanapund S, Mankatitham W, Chimsuntorn S, Sittibusaya C, Moolasart V, Chumpathat N, Termvises P, Chaovavanich A.
    Int J STD AIDS; 2007 Nov 24; 18(11):782-6. PubMed ID: 18005514
    [Abstract] [Full Text] [Related]

  • 18. [Survival and immune response of rural HIV/AIDS patients after free antiretroviral therapy].
    Ding YY, Jia WQ, Wang JS, Dong SL, Yang QH, Zhou RY, Qu SX, Lu LX, Wei J, Qiao XC, Gao MY, Guo XL, Zhang TJ, Wu ZY, He N.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Dec 24; 29(12):1176-80. PubMed ID: 19173958
    [Abstract] [Full Text] [Related]

  • 19. Unrecognised tuberculosis at antiretroviral therapy initiation is associated with lower CD4+ T cell recovery.
    Hermans SM, van Leth F, Kiragga AN, Hoepelman AI, Lange JM, Manabe YC.
    Trop Med Int Health; 2012 Dec 24; 17(12):1527-33. PubMed ID: 23130871
    [Abstract] [Full Text] [Related]

  • 20. First-line highly active antiretroviral regimens in 2001-2002 in the French Hospital Database on HIV: combination prescribed and biological outcomes.
    Potard V, Rey D, Mokhtari S, Frixon-Marin V, Pradier C, Rozenbaum W, Brun-Vezinet F, Costagliola D, French Hospital Database on HIV, ANRS C04.
    Antivir Ther; 2007 Dec 24; 12(3):317-24. PubMed ID: 17591021
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.